Table 2.
Experiment | Treatment group | Anti-WNV-E IgG |
---|---|---|
Mean OD ± S.D. (Range) | ||
a | Alhydrogel™ alone control | 0.02 ± 0.005 (0.01–0.02) |
Baculovirus-produced rWNV-E with Alhydrogel™ 5 μg | 0.47 ± 0.43 (0.03–1.49) | |
Baculovirus-produced rWNV-E alone 5 μg | 0.02 ± 0.01 (0.01–0.04) | |
b | Alhydrogel™ alone control | 0.01 ± 0.002 (0.004–0.01) |
Baculovirus-produced rWNV-E with Alhydrogel™ 5 μg | 0.56 ± 0.52 (0.05–1.36) | |
Drosophila-produced rWNV-E with Alhydrogel™ 5 μg | 0.46 ± 0.38 (0.06–1.25) | |
c | Alhydrogel™ alone control | 0.09 ± 0.08 (0.08–0.10) |
Baculovirus-produced rWNV-E with Alhydrogel™ 2.5 μg | 0.28 ± 0.20 (0.11–0.55) | |
Baculovirus-produced rWNV-E with Alhydrogel™ 5 μg | 0.35 ± 0.32 (0.09–0.84) | |
Baculovirus-produced rWNV-E with Alhydrogel™ 10 μg | 0.73 ± 0.46 (0.13–1.42) |
Serum samples were collected from groups of 10 mice, 2 weeks after immunization. Presence of IgG antibodies against rWNV-E was determined by ELISA at a 1:50 serum dilution.